Skip to content
Review

Emerging Role of Human Long Non-coding RNA HOST2 as a Regulator and Biomarker across Multiple Cancer Types.

Oct 2026 · Current molecular medicine · Vol 26 · 0 citations
Medicine

TL;DR

Clinically, elevated HOST2 expression has been associated with advanced tumor stage, lymph node or distant metastasis, and unfavorable overall survival in several cancer types, suggesting potential value as a prognostic biomarker and therapeutic target.

Abstract

Long non-coding RNAs (lncRNAs) have emerged as important regulators of tumor initiation and progression. Human ovarian cancer-specific transcript 2 (HOST2), also known as competing endogenous lncRNA 2 for microRNA let-7b (CERNA2), is an oncogenic lncRNA that is aberrantly upregulated in several malignancies. This review summarizes current evidence regarding the expression patterns, clinical relevance, and molecular mechanisms of HOST2 in eight cancer types that have been comparatively well studied, including Stomach Adenocarcinoma (STAD), Pancreatic Adenocarcinoma (PAAD), ovarian serous cystadenocarcinoma (OV), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), non-small cell lung cancer (NSCLC), sarcoma (SARC), glioma, and Breast Invasive Carcinoma (BRCA). Mechanistically, HOST2 promotes malignant phenotypes through multiple pathways, most notably by acting as a competing endogenous RNA (ceRNA) for members of the let-7 miRNA family, thereby regulating downstream oncogenic targets. HOST2 has also been implicated in Epithelial-Mesenchymal Transition (EMT), cell-cycle progression, JAK2/STAT3 signaling, and resistance to anticancer drugs such as gemcitabine and gefitinib. Clinically, elevated HOST2 expression has been associated with advanced tumor stage, lymph node or distant metastasis, and unfavorable overall survival in several cancer types, suggesting potential value as a prognostic biomarker and therapeutic target. However, current evidence is derived predominantly from in vitro and in vivo preclinical studies and relatively small retrospective patient cohorts. Further prospective, multicenter, and mechanistic studies are therefore required to validate the clinical utility of HOST2 and to clarify its cancer-specific regulatory functions.

View source

Similar papers

Review Oct 2026

Long Non-coding RNA 01296 in Cancer: A Review of the Current Landscape and Future Directions.

A growing number of studies have shown that long non-coding RNAs (lncRNAs) are essential for the occurrence and progression of a broad spectrum of human malignancies. Long intergenic non-coding RNA 01296 (LINC01296), also known as double homeobox A pseudogene 9 (DUXAP9) and Lymph Node Metastasis-Associated Transcript 1...

Shi-Dong Wang, Si-Fan Liu, Yu-Shuang Xu et al. · 0 citations
Review Open access Oct 2026

Critical roles of the long noncoding RNA SNHG4 in human cancers

Cancer remains a major cause of morbidity and mortality worldwide, with its incidence and mortality rates continuing to rise. The long noncoding RNA SNHG4, a member of the small nucleolar RNA host gene family, has emerged as a candidate regulator in human cancers. This review synthesizes the currently reported expressi...

Yan-Ping Ma, Hai-Ru Zhou · 0 citations
Review Nov 2026

Competing Endogenous Ribonucleic Acid Networks in Cervical Cancer: Mechanisms and Clinical Implications.

Cervical cancer (CC) remains a leading cause of cancer-related mortality among women, with persistent infection with high-risk human papillomavirus (HR-HPV) representing its primary etiological factor. Long non-coding RNAs (lncRNAs), circular RNAs (circRNAs), and pseudogenes can function as competing endogenous RNAs (c...

Li-Juan Shi, Misbah Ullah Khan · 0 citations
Review Nov 2026

Exploratory overview of long non-coding RNAs in lung cancer and diseases: mechanisms and clinical perspectives.

Lung cancer remains one of the leading causes of cancer-related mortality worldwide and continues to present major challenges in diagnosis, prognosis, and treatment. Long non-coding RNAs (lncRNAs) have emerged as important regulators of cancer biology through their ability to modulate gene expression, cellular signalli...

Nithin A. George, G. Tarun, A. G. Dharini et al. · 0 citations
Review Open access Oct 2026

Circular RNAs in Breast Cancer Progression and their Potential Clinical Applications

Owing to their high stability, tissue specificity, and detectability in body fluids, circRNAs have emerged as promising non-invasive biomarkers for diagnosis, prognosis, and treatment monitoring, and advances in RNA-based therapeutics have highlighted circRNAs as attractive therapeutic targets through approaches such a...

A. Abuaisha, H. Arslan, Emir Nekay et al. · 0 citations
#protein folding Open access Oct 2026

Long Non-Coding RNA LINC01614 Promotes Aggressive Phenotypes and Ferroptosis Resistance in Papillary Thyroid Cancer Through a Putative miR-4521/IGF2/PI3K-AKT Signaling Axis

Background/Objectives: Papillary thyroid cancer (PTC) is the most common endocrine malignancy and is generally associated with favorable clinical outcomes. However, a subset of tumors develops aggressive phenotypes characterized by increased proliferation, migration, therapeutic resistance, and disease progression. Lon...

D. Quaranto, N. DeSouza, Michelle Carnazza et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.